Antabio

Description

Antabio develops antibacterial therapies for multidrug-resistant Gram-negative infections and advances Meropenem-Pilabactam, a β-lactam/β-lactamase inhibitor combination for severe drug-resistant infections treated in hospital wards and ICUs.

Antabio is located in the Toulouse ecosystem.

Related

• BialoomBialoom develops silicon plasmo-photonic biosensor biochips embedded in disposable cartridges, quantifying biomarker signatures from…
• STORM TherapeuticsSTORM Therapeutics develops small molecule inhibitors of RNA-modifying enzymes, including STC-15, a METTL3 inhibitor in clinical…
• AACD PharmaACD Pharma develops bacteriophage-based biocontrol products and technologies for preventing and treating bacterial infections, with…
• DebiopharmDebiopharm develops and manufactures pharmaceutical drugs and invests in digital health, focusing on oncology and bacterial infections and…
• BONESUPPORTBONESUPPORT develops the CERAMENT portfolio of bioabsorbable bone graft substitutes that elute gentamicin or vancomycin, provide…
• CamurusCamurus develops and commercializes long-acting pharmaceutical medicines using its proprietary FluidCrystal technology for treatment of…
• OncolinesOncolines provides precision medicine services in oncology and cancer immunotherapy, offering cell‑based assays, profiling platforms,…
• NTrans TechnologiesNTrans Technologies develops a non-viral delivery platform for cell and gene therapies, providing modular delivery solutions for…
• Pharmasum TherapeuticsPharmasum Therapeutics discovers and develops neurological-disease drugs, including PST-674, a proprietary DYRK1A inhibitor intended to…